Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
BeiGene Australia Pty Ltd
Scientific Title
Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors